BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18518782)

  • 1. Treatment strategies for pemphigus vulgaris in Japan.
    Hashimoto T
    Expert Opin Pharmacother; 2008 Jun; 9(9):1519-30. PubMed ID: 18518782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and treatment of pemphigus.
    Tsuruta D; Ishii N; Hashimoto T
    Immunotherapy; 2012 Jul; 4(7):735-45. PubMed ID: 22853759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seeking approval: present and future therapies for pemphigus vulgaris.
    Mao X; Payne AS
    Curr Opin Investig Drugs; 2008 May; 9(5):497-504. PubMed ID: 18465660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pemphigus].
    Lapeyre-LiƩnard H; Joly P
    Presse Med; 2010 Oct; 39(10):1066-70. PubMed ID: 20817387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
    Morrison LH
    J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapies for Pemphigus Vulgaris.
    Altman EM
    Am J Clin Dermatol; 2020 Dec; 21(6):765-782. PubMed ID: 32860200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The actual management of pemphigus.
    Daniel BS; Murrell DF
    G Ital Dermatol Venereol; 2010 Oct; 145(5):689-702. PubMed ID: 20930702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
    Antonucci A; Negosanti M; Tabanelli M; Varotti C
    J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoadsorption in the treatment of pemphigus.
    Mlynek A; Meurer M
    Atheroscler Suppl; 2009 Dec; 10(5):107-9. PubMed ID: 20129386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemphigus vulgaris: approach to treatment.
    Sinha AA; Hoffman MB; Janicke EC
    Eur J Dermatol; 2015 Apr; 25(2):103-13. PubMed ID: 25547117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ; Wolverton SE
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pemphigus: a review].
    Joly P; Sin C
    Ann Dermatol Venereol; 2011 Mar; 138(3):182-200. PubMed ID: 21397148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.
    Salopek TG; Logsetty S; Tredget EE
    J Am Acad Dermatol; 2002 Nov; 47(5):785-8. PubMed ID: 12399777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?
    Tavakolpour S
    Int Immunopharmacol; 2017 Dec; 53():133-142. PubMed ID: 29107213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapy of the pemphigus group.
    Kasperkiewicz M; Schmidt E; Zillikens D
    Clin Dermatol; 2012; 30(1):84-94. PubMed ID: 22137231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pemphigus vulgaris: current and emerging options.
    Yeh SW; Sami N; Ahmed RA
    Am J Clin Dermatol; 2005; 6(5):327-42. PubMed ID: 16252932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.
    Chams-Davatchi C; Esmaili N; Daneshpazhooh M; Valikhani M; Balighi K; Hallaji Z; Barzegari M; Akhyani M; Ghodsi SZ; Seirafi H; Nazemi MJ; Mortazavi H; Mirshams-Shahshahani M
    J Am Acad Dermatol; 2007 Oct; 57(4):622-8. PubMed ID: 17583373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.